Medical/Pharmaceuticals

SineuGene's SNUG01 Receives FDA Orphan Drug Designation for ALS

BEIJING, June 26, 2025 /PRNewswire/ -- SineuGene Therapeutics, a clinical-stage biotechnology company focused on gene therapies for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its gene therapy, SNUG01, for the trea...

2025-06-26 22:04 1876

Ubie Announces Cumulative Total Funding of Over $125M as US Efforts Target Expansion into Generative AI and Provider Solutions

* Ubie's growth has been accelerated by recent strategic investment and acceptance into Mayo Clinic Platform Accelerate program * Ubie's US Symptom Checker platform has seen 85% organic growth and a total user base of 4 million, helping deliver partnerships across patient advocacy and life sc...

2025-06-26 21:00 2270

Porton Advanced and EVA Pharma Sign MOU to Expand CAR T-Cell Therapy Access in The Middle East and Africa

A new era of personalized gene therapy for Leukemia patients in Egypt, Saudi Arabia, and beyond. SUZHOU, China and CAIRO, June 26, 2025 /PRNewswire/ -- Porton Advanced Solutions, a global leading cell and gene therapy CDMO service provider, andEVA Pharma, one of the leading pharmaceutical compan...

2025-06-26 21:00 1820

Alebund Announces Positive Topline Results from Pivotal Phase 3 Study of AP301 for Serum Phosphorus Control in Dialysis Patients with Hyperphosphatemia

SHANGHAI, June 26, 2025 /PRNewswire/ -- Alebund Pharmaceuticals  ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for renal diseases and related chronic conditions, announced the database lock was achieved ...

2025-06-26 20:00 1830

BioCity's ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

* Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal Therapy SHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has ...

2025-06-26 08:38 5089

5K Walk Event in Michigan to Raise Money for Hidradenitis Suppurativa

NEW YORK, June 25, 2025 /PRNewswire/ -- On June 1, Dimora Medical, a continuous innovator in high-end medical care supplies, proudly participated as a sponsor in the HS Connect5K Walk. This event served not only as a fundraising effort but also as an opportunity for education about Hidradenitis S...

2025-06-26 03:27 1698

Medeologix Sets New Standard with 3-Week Lead Time for PET Heat Shrink Tubing

SAN JOSE, Calif., June 25, 2025 /PRNewswire/ -- Medeologix, a leading brand in medical device manufacturing, today announced a significant advancement in their production capabilities that slashes lead times for premium PET heat shrink tubing to just 3 weeks. This milestone is made possible by M...

2025-06-25 23:00 1681

Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders' Meeting Today

TAIPEI and SAN DIEGO, June 25, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, held its 2025 Annual Shareholders' Meeting today, chaired by Chairman Mr.Benny T. Hu. The company delivered updates on its ongoing drug development programs, outl...

2025-06-25 19:00 2112

EDAN Establishes Mexico Subsidiary to Strengthen Presence in the Americas

MEXICO CITY, June 25, 2025 /PRNewswire/ -- EDAN Instruments, Inc. (300206.SZ), a healthcare company and medical device manufacturer, officially celebrated the opening of its new subsidiary, EDAN MEDICAL MÉXICO S de R.L. de C.V., with a ribbon-cutting ceremony held last Wednesday inMexico City. Th...

2025-06-25 18:07 1961

QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA

BRISBANE, Australia, June 25, 2025 /PRNewswire/ --   QBiotics CEO, Stephen Doyle, reflecting on Soft Tissue Sarcoma data * Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced S...

2025-06-25 18:05 1968

Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...

2025-06-24 22:02 2559

PanBrain Tech Unveils Breakthrough Brain-Computer Interface Device at BEYOND EXPO 2025 in Macau

MACAU, June 23, 2025 /PRNewswire/ -- Brain science technology company PanBrain Tech Co., Ltd. drew widespread attention at the BEYOND International Technology Innovation Expo 2025 inMacau with the debut of its flagship brain-computer interface (BCI) device, thePanBrain ...

2025-06-23 21:00 4163

OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer

PRINCETON, N.J., June 23, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today announced the appointment ofDimitry S.A. Nuyten, M.D.,...

2025-06-23 19:55 1627

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)

SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that results from an ...

2025-06-23 10:01 2188

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a global strategic collabora...

2025-06-23 08:03 2020

Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations

SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy and safety of sunvozertinib versus platinum-based doublet chemotherapies as a first-line treatment for...

2025-06-19 18:08 2315

111, Inc. Announces First Quarter 2025 Unaudited Financial Results

* Maintained Quarterly Operational Profitability * Operating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoY * Maintained Quarterly Positive Operating Cash Flow SHANGHAI, June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled h...

2025-06-19 15:03 4554

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

SHANGHAI, June 18, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment in the ongoing Phase 1 trial (SIM0500-101,NCT06375044

2025-06-19 08:37 2109

MedHub-AI Receives PMDA Approval in Japan for AutocathFFR®

TEL AVIV, Israel, June 18, 2025 /PRNewswire/ -- MedHub-AI , a global leader in AI-powered cardiovascular diagnostics, announced today that the Pharmaceuticals and Medical Devices Agency (PMDA) inJapan has approved AutocathFFR®, the company's non-invasive, AI-driven sof...

2025-06-19 07:00 3194

Medison Expands Global Leadership Team with Chief Business Officer and Chief Legal & Compliance Officer

Strategic appointments reflect Medison's continued investment in global scale and operational excellence PETACH TIKVA, Israel, June 18, 2025 /PRNewswire/ -- Medison , the creator of a first-of-its-kind unified global commercialization platform that accelerates the...

2025-06-18 22:36 1834
1 ... 24252627282930 ... 248

Week's Top Stories